Abstract:Abstract Antibodies and antibody containing therapeutics, such as multivalent antibodies, chimeric antigen receptors (CARs), and antibody directed conjugates (ADCs), have been proven to be highly prominent in cancer treatment. However, challenges such as immunogenicity stemming from non-human or unnatural sequences and limitations in preclinical animal study systems still impede the rapid development of antibody drugs. To overcome these hurdles, GemPharmatech has created a novel antibody gene humanized model, the NeoMab mouse, to develop fully human antibodies. The NeoMab model was established via large genomic fragment knock-in technology, retaining native mouse constant region encoding genes and regulatory elements, while incorporating human variable gene repertoires into the endogenous loci. Developed in the BALB/c background, the NeoMab mouse carries fully functional MHC molecules, potentially enhancing antigen presentation. These mice sustain a competent immune system with a B cell development and maturation pattern, immune cell profile, and serum immunoglobulin levels comparable to those of BALB/c mice. NeoMab mice exhibit a robust humoral immune response, with a rapid increase in antigen-specific serum titers upon immunization using different antigens, such as recombined protein, plasmids, and overexpressing cell lines. Utilizing human V(D)J genes to encode immunoglobulins at a human-like frequency and diversity, antibodies derived from NeoMab mice demonstrate affinity and functional activity comparable to, or even surpassing, FDA-approved drugs. In conclusion, the NeoMab mouse model in the BALB/c background has been rigorously validated to elicit a robust response to specific antigen immunization, producing antibodies with high affinity, diversity, and functional activity. GemPharmatech's extensive drug-target gene humanized mouse library (comprising over 800 targets) and diverse disease models in oncology and other fields facilitate a seamless connection between in vitro antibody screening and in vivo animal studies. The integration of NeoMab, target humanization animals, and disease models enables GemPharmatech to provide an integrated solution, reducing time and costs while elevating the quality of antibody discovery in the field. Citation Format: Mingkun Zhang, Cunxiang Ju, Song Li, Junchao Peng, Jing Zhao, Xiang Gao. NeoMab: A novel platform for fully human therapeutic antibody development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5333.

A novel and effective approach to generate germline-like monoclonal antibodies by integration of phage and mammalian cell display platforms

Successful construction and massive expression of a novel Anti-CD19 human-mouse chimeric antibody Hm2E8b.

A general Fc engineering platform for the next generation of antibody therapeutics

Affinity Maturation of Antiher2 Monoclonal Antibody Mil5 Using an Epitope-Specific Synthetic Phage Library by Computational Design

[Production of phage-displayed single chain variable fragments of monoclonal antibody MGb1].

Construction, Expression, and Characterization of a Novel Human-Mouse Chimeric Antibody, Hm3A4: A Potential Therapeutic Agent for B and Myeloid Lineage Leukemias.

Mammalian cell display for the discovery and optimization of antibody therapeutics

Potent Germline-Like Monoclonal Antibodies: Rapid Identification of Promising Candidates for Antibody-Based Antiviral Therapy

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Modification of phage display technique for improved screening of high-affinity binding peptides

Designing and constructing a phage display synthesized single domain antibodies library based on camel VHHs frame for screening and identifying humanized TNF-α-specific nanobody

Abstract 5333: NeoMab: A novel platform for fully human therapeutic antibody development

Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

The role of phage display in therapeutic antibody discovery

Generation and Next-Generation Sequencing-Based Characterization of a Large Human Combinatorial Antibody Library

Discovery of a fully human antibody to the proximal membrane terminus of MUC1 based on a B-cell high-throughput screening technique

Optimizing effector functions of monoclonal antibodies via tailored N-glycan engineering using a dual landing pad CHO targeted integration platform

Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics

Evolution of phage display libraries for therapeutic antibody discovery

Advancement in the development of single chain antibodies using phage display technology

A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies